Takeda’s NDA for fomepizole gets approval in Japan
Fomepizole is marketed and distributed by Paladin Labs (Paladin) in Canada and is the standard treatment for ethylene glycol and methanol poisonings. In 2011, Paladin and Takeda entered
Fomepizole is marketed and distributed by Paladin Labs (Paladin) in Canada and is the standard treatment for ethylene glycol and methanol poisonings. In 2011, Paladin and Takeda entered
Harvoni is a combination of the NS5A inhibitor ledipasvir (LDV) 90mg and the nucleotide analog polymerase inhibitor sofosbuvir (SOF) 400mg. The European Commission, which has the authority to
The CHMP recommendation is for the use of Lymphoseek in imaging and intraoperative detection of sentinel lymph nodes draining a primary tumor in adult patients with breast cancer,
The approval is for nintedanib (Vargatef) in combination with docetaxel to treat adults with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumor
The IND application includes a pivotal Phase III protocol for Neutrolin in hemodialysis patients with a central venous catheter. The multi-centre, randomised, controlled trial is conducted in the
Prior to becoming a public company, Livzon was a principal investor in the $36m private financing round EPIRUS that closed in April 2014. EPIRUS’ Remicade biosimilar BOW015 (infliximab)
The joint laboratory will focus on the discovery and development of new biologic cancer treatments over an initial five-year period. Under the deal, scientists from both organisations will
Crohn’s disease is a type of inflammatory bowel disease (IBD) which involves the end of the small intestine and the large intestine. The FDA approval represents the eighth
The new unit will be aimed at identifying new approaches and targets for obesity treatments while increasing the scientific understanding of existing obesity targets. Initially, around ten people
In addition, the companies have formed a partnership that will leverage the strengths of both organizations to identify and develop new drugs. The five-year investment gives Takeda the